CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Biotech
Original article

GEVORKYAN in H1 2026: Revenue +18%, Net Profit +34%

EarningsPositive
AI Analysis

Summary

GEVORKYAN reported H1 2026 financial results with revenue growth of 18% and net profit growth of 34%.

Financial Highlights

Revenue

+18%

Importance:2/10
Sentiment:
0.60
earningsH1 2026revenue growthnet profit growth

Read the original article

Published by GlobeNewswire Biotech on September 15, 2026 6:00 AM

Read Original